Abstract
Two hundred and twenty-eight acute paranoid psychotic in-patients received continuous treatment with perphenazine for a period of at least 5 weeks, before blood samples were taken to determine perphenazine plasma levels and conclusions regarding therapeutic efficacy and motor side effects. Patients with plasma concentrations within the range of 2–6 nmol/l showed an excellent antipsychotic response, concomitantly with a low incidence of extrapyramidal side effects. However, patients with plasma levels below or above this range either demonstrated a poor therapeutic response or a high degree of side effects respectively. The results indicate that with increasing age significantly lower doses of perphenazine are required to ensure an optimal clinical response. No difference, however, was seen between sexes with regard to dose response.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bolvig Hansen L, Larsen N-E (1977) Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology 53:127–130
Bolvig Hansen L, Elley J, Christensen T, Larsen N-E, Naestoft J, Hvidberg EF (1979) Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs. Br J Clin Pharmacol 7:75–80
Bolvig Hansen L, Larsen N-E, Vestergaard P (1981) Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacology 74:306–309
Bolvig Hansen L, Larsen N-E, Gulmann N (1982) Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology 78:112–115
Cooper TB (1978) Plasma level monitoring of antipsychotic drugs. Clin Pharmacokinet 3:14–38
Ericksen SE, Hrut SW, Chang S (1978) Haloperidol dose, plasma levels and clinical response: A double-blind study. Psychopharmacol Bull 14:15–16
Extein I, Augusthy KA, Gold MS, Pottash ALC, Martin D, Potter WZ (1982) Plasma haloperidol levels and clinical response in acute schizophrenia. Psychopharmacol Bull 18:156–158
Forsman A, Ohman R (1977) Applied pharmacokinetics of haloperidol in man. Curr Ther Res 21:396–411
Hansen CE, Rosted Christensen T, Elley J, Bolvig Hansen L, Kragh-Sorensen P, Larsen N-E, Naestoft J, Hvidberg E (1976) Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol 3:915–923
Kragh-Sorensen P, Larsen N-E (1980) Factors influencing nortriptyline steady-state kinetics. Clin Pharmacol Ther 28:796–803
Magliozzi JR, Hollister LE, Arnold KV, Earle GM (1981) Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Am J Psychiatry 138:365–367
Meitzer HY, Kane JM, Kolakowska T (1983) Plasma levels of neuroleptics, prolactin levels, and clinical response. In: Coyle JT, Enna SJ (eds) Neuroleptics: Neurochemical, behavioral, and clinical perspectives. Raven, New York, pp 255–281
Smith RC, Crayton J, Dekirmenjian H, Klass D, Davis JM (1979) Blood levels of neuroleptic drugs in nonresponding chronic schizophrenic patients. Arch Gen Psychiatry 36:579–584
Smith RC, Vroulis G, Shvartsburd A, Allen R, Lewis N, Schoolar JC, Chojnacki M, Johnson R (1982) RBC and plasma levels of haloperidol and clinical response in schizophrenia. Am J Psychiatry 139:1054–1056
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hansen, L.B., Larsen, NE. Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology 87, 16–19 (1985). https://doi.org/10.1007/BF00431770
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00431770